|
楼主 |
发表于 2015-2-6 10:10:49
|
显示全部楼层
本帖最后由 vmzy 于 2015-2-6 10:23 编辑
Src kinase: Project 10471
January 26, 2015 by Sonya Hanson ·
In Project 10471 we at the Chodera lab are looking at Src kinase. The Src gene was first discovered as responsible for the tumorogenicity of Rous sarcoma virus. This gene is also present in animals, and it is in fact a mutated Src gene that is injected back into the host that causes cancer, not a viral gene. The discovery that cancer was a result of mutated naturally occuring genes and not viral ones was a milestone in cancer research and Harold E. Varmus and J. Michael Bishop were awarded the Nobel Prize in Physiology or Medicine for this and related discoveries of the cellular origin of retroviral oncogenes in 1989.
Since then Src has been found to be over-expressed and/or highly activated in a variety of cancers, most notably linked to metastasis in breast, prostate, and colon cancers. The drug dasatinib of Bristol-Myers Squibb (Sprycel commercially), has been approved for treatment of CML (described more fully in our blog post on Abl kinase), but it was also recently in clinical trials for metastatic prostate cancer due to its affinity for Src kinase.
We are not only interested in Src kinase for its intrinsic value, but also to compare and contrast its behavior with Abl kinase in Project 10472. While dasatinib targets both Src and Abl kinase, only Abl and not Src is sensitive to the drug imatinib, despite the nearly identical imatinib bound poses seen in the Src and Abl crystal structures (pictured). Because these static structures are so similar, we are looking forward to using the long timescale simulations of these two kinases on Folding@home to help us understand their different small molecule binding properties.

大意:
10471项目主要研究Src激酶,在很多癌症(如:乳腺癌,前列腺癌,直肠癌)中Src激酶都会出现过度表达。现有药物达沙替尼对Src激酶有效。
10472项目主要研究Abl激酶。虽然达沙替尼和伊马替尼的靶点都是一样的,但是伊马替尼只对Abl激酶有效,对Src激酶无效。对此我们将对两种激酶进行横向对比,以期发现其中的奥秘所在。
Cancer Systems Biology Scholars Program
January 28, 2015 by Vijay Pande ·

I’m happy to announce our participation in the Cancer Systems Biology Scholars (CSBS) program, which provides a unique opportunity for postdoctoral training in cancer systems biology in a dynamic, multi-disciplinary environment. A diverse group of mentors, all with independently funded research projects in cancer research, participate with expertise in many disciplines. CSBS trainees will conduct research, participate in specialized coursework and seminars, and attend a regular meeting of CSBS mentors and trainees, as part of an integrated, two-year program.
For those looking to be a postdoctoral fellow in the program, I encourage you to apply:
http://med.stanford.edu/csbs/apply/
This would be an opportunity to work on Cancer in the Pande Lab/Folding@home or with any of the other mentors associated with the CSBS at Stanford. The application deadline is March 2, 2015. Priority will be given to applications received by March 2. Applications received after March 2 will be considered until positions are filled.
大意:
Pande实验室加入了癌症系统生物学者培养计划,博士后可以申请加入。
Big Adv Program Ends January 31
January 31, 2015 by Vijay Pande ·
As we have previously announced, the bigadv (BA) program will reach end-of-life on January 31, 2015. We would like to thank all the donors who have contributed to the program. Throughout the history of Folding@home, donor participation has enabled us to tackle hard problems and engage in bold experiments. The BA program is an example of both of these––the projects in BA are one that simply could not have been addressed otherwise. We are still analyzing the results of these projects, but the preliminary data already yields some exciting results that we are comparing to experiments.
Although the BA program is ending, we recognize that the many-core systems previously used to run BA may not perform optimally on all work units in the Folding@home ecosystem (although they will do quite well on most). In an ideal world, we would have each project performance-benchmarked on a wide variety of systems and a dynamic allocation scheme that matches clients to projects that perform well on their hardware while ensuring a distribution of client capability across Folding@home scientific priorities. However, this sort of matching is more technically involved (and places larger demands on the assignment server) than we are able to offer at this time. At BA end-of-life, in order to make sure that these many-core get WUs best suited for them, clients continuing to use the BA flags will be directed to large work units, although these will carry the normal Folding@Home points scheme rather than a BA scheme. We are planning to expand the diversity of these work units to include a variety of “large” simulation problems, but at this point we are not making statements as to the anticipated longevity of this scheme.
Thank you once again for contributing to Folding@home, whether the BA program or any of our other initiatives. All our past and future scientific achievements are due to your participation and generosity.
大意:
BA项目将于1月31日结束。BA的结果还在分析中,早期的数据生成了令人振奋的结果,我们还在和实验室数据进行比对。
虽然BA项目结束了,但是我们发现参与BA的‘类超级计算机’如果直接算普通的SMP任务,会对现有的积分系统和任务服务器,产生一定影响。所以对于加了BigAdv标签的用户,我们将放出定制的大包。不过将采用普通任务的奖励标准。
Huntington’s Disease Society of America SF Celebration of Hope
January 29, 2015 by Vijay Pande ·
HD-SF-2015On Saturday May 30th, 2015, the Huntington’s Disease Society of America SF Celebration of Hope will Honor Prof. Pande for his work with Folding@home. Details are in poster to the right (click on it to enlarge it) and this link.

大意:
2015年旧金山亨廷顿舞蹈症希望之家,为Pande教授颁奖,以感谢他和FAH在疾病研究方面做出的贡献。 |
|